Japanese Journal of Clinical Oncology 30:59-64 (2000)
© 2000 Foundation for Promotion of Cancer Research
Phase II Trial of Daily Low-dose Carboplatin and Thoracic Radiotherapy in Elderly Patients with Locally Advanced Non-small Cell Lung Cancer
1Department of Internal Medicine, National Kinki Central Hospital for Chest Diseases, Osaka, 2Department of Internal Medicine, Osaka Prefectural Habikino Hospital, Osaka, 3Osaka City University, Osaka and 4Osaka City General Hospital, Osaka, Japan
Background: The purpose of this study was to investigate the feasibility of concurrent thoracic radiotherapy (TRT) and daily low-dose carboplatin (CBDCA) in elderly patients with locally advanced non-small cell lung cancer (NSCLC) and to estimate tumor response, toxicity and survival.
Methods: Forty patients were entered in a multicenter phase II study. All were patients with pathologically documented unresectable stage IIIA or IIIB or medically inoperable stage I, II NSCLC. CBDCA 30 mg/m2 was given on days 1–5 in weeks 1–4 concurrently with TRT, mainly for radiosensitization. TRT was started 1 h after CBDCA (30 min infusion) was given. TRT was given in 2 Gy/fraction/day, 5 days a week for a total of 50–60Gy.
Results: Thirty-eight patients were assessable for treatment response and toxicity. One patient had a CR and 18 patients PRs with a response rate of 50% (95% CI, 33.4–66.6%). The main toxicities were hematological toxicity. Other toxicities were grade 
2 esophagitis in one patient, grade 3 nausea/vomiting in one and grade 3 pulmonary toxicity in two. There was one treatment-related death due to pulmonary toxicity. For stage IIIA + IIIB patients, the median survival time was 15.1 months and 1-and 2-year actuarial survival rates were 52.6 and 20.5%, respectively. For stage I + II patients, 1- and 3-year actuarial survival rates were 90.9 and 69.3%, respectively.
Conclusions: The data suggest that TRT with daily low-dose CBDCA in elderly patients is effective and feasible because of its low toxicity and survival.
+ For reprints and all correspondence: Shinji Atagi, Department of Internal Medicine, National Kinki Central Hospital for Chest Diseases, 1180 Nagasone, Sakai, Osaka 591-8555, Japan. E-mail: atagi@kinchu.hosp.go.jpAbbreviations: NSCLC, non-small cell lung cancer; TRT, thoracic radiotherapy; CBDCA, carboplatin
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Gridelli, C. Langer, P. Maione, A. Rossi, and S. E. Schild Lung Cancer in the Elderly J. Clin. Oncol., May 10, 2007; 25(14): 1898 - 1907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Jeremic, B. Milicic, L. Acimovic, and S. Milisavljevic Concurrent Hyperfractionated Radiotherapy and Low-Dose Daily Carboplatin/Paclitaxel in Patients With Early-Stage (I/II) Non-Small-Cell Lung Cancer: Long-Term Results of a Phase II Study J. Clin. Oncol., October 1, 2005; 23(28): 6873 - 6880. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Atagi, M. Kawahara, T. Tamura, K. Noda, K. Watanabe, A. Yokoyama, T. Sugiura, H. Senba, S. Ishikura, H. Ikeda, et al. Standard Thoracic Radiotherapy With or Without Concurrent Daily Low-dose Carboplatin in Elderly Patients with Locally Advanced Non-small Cell Lung Cancer: a Phase III Trial of the Japan Clinical Oncology Group (JCOG9812) Jpn. J. Clin. Oncol., April 1, 2005; 35(4): 195 - 201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. M. Groen, A. H. W. van der Leest, E. Fokkema, P. R. Timmer, G. D. Nossent, W. J. G. M. Smit, J. Nabers, H. J. Hoekstra, J. Hermans, R. Otter, et al. Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study Ann. Onc., March 1, 2004; 15(3): 427 - 432. [Abstract] [Full Text] [PDF]
|
|